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Background: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired
chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1
receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving.
Methods: We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by
immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of
CRC and RNAi for functional validation.
Results: Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor
overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear
compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear
sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used
in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R.
Conclusions: Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
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Colorectal cancer (CRC) is one of the most commonly diagnosed
cancers and a leading cause of death worldwide (Brenner et al,
2014). Despite currently available first-line treatments with
FOLFOX or FOLFIRI and the implementation of targeted
therapies such as bevacizumab, panitumumab or cetuximab, the
median progression-free survival (PFS) has only improved
modestly (9–10 months) and most patients with metastatic
colorectal cancer (mCRC) are not cured (Saltz et al, 2008; Van
Cutsem et al, 2011). Acquired resistance to chemotherapy and
targeted agents is a major obstacle to survival in patients with
mCRC.
The type 1 insulin-like growth factor receptor (IGF-1R) is a
transmembrane glycoprotein composed of two extracellular units
and two cytoplasmic subunits acting as a receptor tyrosine kinase.
IGF-1R is overexpressed in many human cancers (Pollak, 2008;
Baserga, 2009) and its activation at the plasma membrane mediates
key processes in cancer, such as cell growth, cell proliferation,
differentiation, apoptosis, angiogenesis, and anchorage indepen-
dent growth DNA damage repair (Werner and LeRoith, 1996;
Baserga, 1999; Girnita et al, 2000). The main signalling pathways
involved in IGF-1R are PI3K-AKT and MAPK pathways. IGF-1R
has become a target of novel therapeutics, specifically monoclonal
antibodies and small molecules targeting inhibition of the tyrosine
kinase activity.
Several receptor tyrosine kinases such as EGFR, HER2, HER3,
HER4, FGFR1, and FGFR3 are known to undergo nuclear
translocation in human cancers (Johnston et al, 1995; Lin et al,
2001; Wang et al, 2004). Upon ligand binding of IGF-1 or IGF-2
to the IGF-1R and constitutional activation of the signalling
pathway, the IGF-1R undergoes endocytic internalisation by
clathrin-coated vesicles (Salani et al, 2010), and subsequent
ubiquitination and degradation by the proteasome (Sehat et al,
2007). It has been recently described that sumoylation of IGF-1R
at three evolutionary conserved lysine residues is critical for the
nuclear translocation (Sehat et al, 2010; Deng et al, 2011), and
once inside the nucleus, IGF-1R would play a role as a
transcriptional co-activator of LEF1/TCF complex, increasing
the transcription of downstream target genes such as Cyclin D1
and Axin 2 (Warsito et al, 2012). Sumoylation of IGF-1R seems
to be required for interaction with RanBP2, a nuclear pore
complex protein crucial for the nucleo-cytoplasmic trafficking,
which may favour nuclear IGF-1R accumulation by increasing
the stability of the receptor (Packham et al, 2014). Specifically,
RANBP2 binds to RANGAP1*SUMO1 and Ubc9, and forms an
autonomous machine that disassembles Crm1-dependent
nuclear export complexes (Ritterhoff et al, 2016). Recent reports
have described the presence of IGF-1R within the nucleus of
human tumour renal cells, pre-invasive lesions in the breast and
in proliferative non-malignant tissues (Aleksic et al, 2010).
According to the same authors, nuclear translocation of IGF-1R
is associated with poor prognosis in renal cancer and may
influence the efficacy of IGF-1R inhibitory drugs. In BRAF-like
colon cancer cells, it has been recently shown that the loss of
RANBP2 induces greater cell death upon treatment with
vinorelbine due to the malfunctioning of the kinetochore during
mitosis (Vecchione et al, 2016). However, whether the inter-
nalisation of nuclear IGF-1R plays a role in resistant CRC
remains totally elusive.
In addition, despite that some CRC cell lines are sensitive to
anti-IGF-1R compounds (both monoclonal antibodies and tyr-
osine-kinase inhibitors) (Flanigan et al, 2010; Ii et al, 2011), several
trials in heavily pre-treated mCRC patients with anti-IGF-1R
compounds (Cohn et al, 2013; Van Cutsem et al, 2014) showed
only modest efficacy. We therefore sought to understand the
potential role that nuclear translocation of IGF-1R might have
during the acquisition of chemo-resistance to conventional and
targeted therapies in CRC.
MATERIALS AND METHODS
Patient samples. To evaluate the prognostic role of nuclear
p-IGF-1R, we analysed four cohorts of mCRC patients. The
SIEMENS-2 cohort consisted of 279 mCRC patients treated with
FOLFOX-6 or CAPOX (Alonso-Orduna et al, 2014). The BECOX
trial consisted of 68 mCRC patients treated with CAPOX plus
bevacizumab (NCT01067053) (Feliu et al, 2014). The PULSE trial
consisted of 185 screened mCRC patients of which 78 WT KRAS
(exon 2) were included and treated with FOLFOX-6 plus
panitumumab (NCT01288339) (Maurel et al, 2016). The POSIBA
trial consisted of 212 WT KRAS (exon 2) patients treated either
with FOLFOX-6 or FOLFIRI plus biweekly cetuximab
(NCT01276379) (Alonso et al, 2016). Since anti-EGFR compounds
are approved currently only in all RAS WT patients, we excluded
patients from the PULSE and POSIBA trials with mutations in
KRAS (exons 3 and 4) and NRAS. We studied the patterns and
nuclear expression of p-IGF-1R and its association with RAS and
BRAF genotypes in available samples from 563 mCRC patients. We
also assessed changes of nuclear p-IGF-1R expression in samples
taken after treatment with anti-EGFR þ / irinotecan as second
or third line of therapy in 44 patients with paired biopsies in a
different cohort of mCRC patients.
The paired biopsy biomarker and SIEMENS-2 studies were
approved by the institutional Ethics Committee of Hospital Clı´nic
Barcelona. The BECOX, PULSE and POSIBA trials were approved
by local institutional review boards and ethics committees in
accordance with national and international guidelines; all patients
signed a written informed consent document.
Cell lines. Human colorectal carcinoma cell lines HT29, DLD-1,
HCT116, SW1116, Colo320, SW480, SW403, SW1463 and SW837
were obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and cultured according to ATCC conditions.
HT29-OxR and DLD-1-OxR are oxaliplatin resistant cell lines
generated from HT29 and DLD1 parental cell lines respectively,
kindly provided by Dr Albert Abad from Hospital Germans Trias i
Pujol (Barcelona, Spain).
Tissue microarray and biopsies. Tissue microarrays were per-
formed from representative tumour areas selected from paraffin
blocks of surgical specimens. Each tumour was represented by four
1mm diameter cores. Several consecutive 2–3mm cuts of each
TMA were performed and stained with haematoxylin and eosin
and immunohistochemistry (IHC). In patients for whom surgical
specimens were not available, whole sections of the previous
diagnostic endoscopic biopsies were used for IHC staining.
Mutational analysis. Mutational analysis of RAS was performed
by direct sequencing after COLD-PCR amplification. The BRAF
V600E genomic mutation in exon 15 was genotyped by allelic
discrimination in genomic DNA using TaqMan technology on a
7300 Real Time PCR System (Applied Biosystems, Foster City, CA,
USA).
Cell viability assay. The effect on cell viability of 5-fluorouracil (5-
FU), oxaliplatin, sorafenib and ganitumab were studied by using
the colorimetric method provided by MTS-Cell Titer 96 Aqueous
Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison,
WI, USA). Briefly, 2000 cells were seeded in 100 ml drug-free media
and incubated for 24 h before drug treatment in 96-well flat-
bottomed plates (Nunc, Naperville, IL, USA). Incubations were
performed for 72 h and absorbance generated were measured on an
Epoch microplate spectrophotometer (BioTek Instruments,
Winooski, VT, USA). Data were derived from three independent
experiments.
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Reagents and antibodies. The following reagents and drugs were
used in this study: Ganitumab (Amgen, Thousand Oaks, CA, USA),
an anti-IGF-1R monoclonal antibody; NVP-AEW541 (Novartis,
Basel, Switzerland), a tyrosine kinase inhibitor of IGF-1R; sorafenib
(Bayer, Leverkusen, Germany), a multikinase inhibitor (C-Raf, B-Raf,
VEGFR2, VEGFR3, PDGFRb and C-Kit); cetuximab (provided by
the Hospital Clı´nic Pharmacy Unit), monoclonal antibody against
EGFR; TIMP-1 (Chemicon International Inc., Temecula, CA, USA),
a matrilysin inhibitor; dasatinib (LC laboratories, Woburn, MA,
USA), an inhibitor of BCR-ABL kinase and Src-family kinases;
dynasore (Sigma-Aldrich, Saint Louis, MO, USA), an inhibitor of
endocytic vesicle formation; curcumin (Sigma-Aldrich); leptomycin
B (Selleckchem, Houston, TX, USA), a specific nuclear traffic
inhibitor through CRM1; oxaliplatin (Sigma-Aldrich); and 5-FU
(provided by the Hospital Clı´nic Pharmacy Unit).
The primary antibodies used for western blot were tubulin
(Sigma-Aldrich), PARP (Roche, Basel, Switzerland), IGF-IR,
p-IRS-1, AKT, p-AKT (Ser473), ERK 1/2, p-ERK 1/2, BAX,
BCL-2, PIAS3, GAPDH (Cell Signaling Technologies, Danvers,
MA, USA), HDAC1 (Rockland, Limerick, PA, USA), and phospho-
IGF-1R (Y1316) (kindly provided by Dr M. Rubini from University
of Ferrara, Italy). Species-specific HRP-linked antibodies (GE
Health Care, Little Chalfont, UK) were used for secondary
labelling. For immunofluorescence, we used the following
antibodies: mouse anti-E-cadherin (Transduction Lab, San Diego,
CA, USA), and rabbit anti-phospho-IGF-1R (Y1316). Alexa Fluor
594 goat anti-rabbit (Life Technologies, Carlsbad, CA, USA) was
used as a secondary antibody.
Immunostaining. We used haematoxylin and eosin staining to
select representative sections of the tumour for immunostaining.
The above-mentioned list of colorectal carcinoma cells lines was
cultured, trypsin-based detached and centrifuged. The resulting
pellet was formalin-fixed and paraffin-embedded in a cellular block
using the plasma-thrombin method. Multiple consecutive 2–3-mm-
thick sections were performed for IHC. One slice was stained with
haematoxylin and eosin for morphologic control, while the others
were used for IHC stains. Removal of paraffin was performed with
xylene and decreasing concentrations of ethanol. Heat antigen
retrieval was achieved by incubation of the slides in pH 6.0 buffer
citrate at 10 1C for 20min. Primary p-IGF-1R antibody was used at
1 : 100, and incubated for 1 h. Secondary antibody, detection and
revealed was performed using the Dako (Carpinteria, CA, USA)
EnVision K4011 (Dako). Nuclear positivity was recorded using a
conventional Olympus BX41 microscope (Olympus, Tokyo,
Japan), and defined as negative (0% of cells with nuclear staining),
low (1–19% of cells with nuclear staining) or high (X20% of cells
with nuclear staining) expression.
For immunofluorescence, paraffin from 3 mm primary sample
sections was removed and the samples were heated in citrate pH
6.0 for antigen retrieval. Slides were permeabilised in PBS with
triton 0.5%, blocked with normal donkey serum 3%, and incubated
with the primary antibody overnight. We performed nuclear
staining using TO-PRO-3 stain (1 : 50 000; Life Technologies).
Additionally, HT29 and HT29-OxR cell lines were cultured on
glass cover slips (Thermo Fisher Scientific, Carlsbad, CA, USA) to
40–50% confluence. After 24 h incubation, the cells were fixed with
4% cold paraformaldehyde and permeabilised in 0.15% Triton
X-100. Fixed cells were blocked and incubated with primary
antibodies overnight at 4 1C. Next day, slides were washed and
incubated for 1 h with the corresponding secondary antibody. After
washing the slides with PBS, we used Prolong Gold Antifade
Reagent with DAPI (Life Technologies) for mounting. Images were
acquired with a Leica TCS SP5 confocal microscopy (Leica,
Wetzlar, Germany), and were processed and analysed with ImageJ
software. Results are expressed as the mean±s.e.m., unless
otherwise indicated.
Western blot analysis. Cells were cultured in six-well plates or
100mm cell culture dishes and total protein extract was obtained.
Briefly, for cytoplasmic and nuclear extracts, the Nuclear/Cytosol
Fractionation kit (BioVision, San Francisco, CA, USA) was used.
Proteins were resolved on SDS–polyacrylamide gels and electro-
phoretically transferred to polyvinyllidene fluoride membranes.
Membranes were blocked in 5% TBS containing non-fat dried milk
and then incubated for 1 h. After this, the membrane was
incubated with primary antibody overnight at 4 1C and then with
the corresponding secondary antibody for 2 h. Enhanced chemi-
luminescence was used according to the manufacturer’s instruc-
tions (SuperSignal West Dura Chemiluminiscent Substrate,
Thermo Fisher Scientific).
Small interfering RNA. Gene silencing was performed by using
the SMART pool siRNA against PIAS3 and the corresponding
controls (Dharmacon, Lafayette, LA, USA, Thermo Fisher
Scientific). Lipid-based transfections were achieved with Lipofec-
tamine 2000 (Life Technologies) according to the manufacturer’s
protocol. Cells were incubated with the siRNA complex for 72 h
and protein was extracted for assessing transfection efficiency by
western blot.
Statistical analysis. For primary samples, Wilcoxon score test and
chi-square test were used. Mann–Whitney U test was performed
for assessing statistical differences in parental and chemo-resistant
cell lines.
Clinical end-points were response rate, PFS and overall survival
(OS). Tumour assessment by computed tomography scan was
performed every 2–3 months until progressive disease. Patients
without a second computed tomography evaluation were not
assessable for response rate. PFS was defined as the time of the
initial first-line chemotherapy dose until disease progression, death
from any cause or administrative end of follow-up, whichever
occurs first. Overall survival was defined as the time from first-line
chemotherapy initiation to death for any cause or administrative
end of follow-up, whichever is first. Kaplan–Meier curves were
used to plot PFS and OS. Cox proportional hazard regression was
used to perform the survival analysis. All P-values were two-sided.
Analysis was performed by using SAS V9.4 (SAS Institute, Cary,
NC, USA) statistical software.
RESULTS
Nuclear expression of p-IGF-1R predicts poor survival in mCRC
patients treated with first-line chemotherapy and targeted
agents. First, we evaluated the pattern of p-IGF-1R expression
by IHC in 563 samples from mCRC patients. Representative cases
of membrane, perinuclear, negative and exclusive nuclear p-IGF-
1R IHC staining are shown in Figure 1A. Nuclear p-IGF-1R
staining was present in 35% of patients in the SIEMENS-2 cohort,
in 36% in the BECOX trial and in 16% of patients in the PULSE
and POSIBA trials. The frequency of nuclear p-IGF-1R expression
was significantly higher in BRAF mutant (49%) compared to RAS
mutant (14%) or double wild-type (2WT) (23%) patients
(Po0.0001). In addition, cases with p-IGF-1R expression identi-
fied exclusively in the nucleus were higher in BRAF mutant (16%)
than in RAS mutant (2%) or 2WT (4%) patients (Po0.0001)
(Supplementary Table S1). A summary of the patient character-
istics is shown in Supplementary Table S1. For those patients with
available clinical information (n¼ 470), our analysis showed that
nuclear p-IGF-1R was associated with poor eastern cooperative
oncology group scale of performance status (P¼ 0.001), high
alkaline phosphatase levels (P¼ 0.013) and BRAF mutation
(Po0.0001) (Table 1).
For 44 mCRC patients, primary tumour and paired metastatic
biopsies (second or third biopsies) were available. Paired biopsies
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were obtained from patients without previous therapy for
advanced disease (n¼ 12), after treatment with chemotherapy
alone (n¼ 27), or after treatment with chemotherapy and
anti-EGFR (n¼ 5). The concordance rate of p-IGF-1R in the
nucleus assessed by IHC analysis between primary and paired
metastases was 98% (Figure 1B). An increment of the nuclear
p-IGF-1R in the metastasis compared to its matched primary
samples was observed in 11% of the cases. Representative images of
the increased levels of nuclear p-IGF-1R expression in metastatic
samples (after chemotherapy and after chemotherapy and anti-
EGFR therapy) compared to the matched primary untreated
tumours are shown in Figure 1C. Of note, none of the initially
nuclear p-IGF-1R negative patients in the primary tumour became
positive at its paired metastases, regardless of which treatment they
received.
Mutational status for BRAF and KRAS was also assessed. Forty-
six patients (10%) that presented the V600E mutation in BRAF,
showed a significantly inferior OS (median 11.2 months [95% CI,
7.6–14.9]) compared to 2WT disease (median 30.7 months [95%
CI 26.1–35.2]) and RAS mutant disease (median 25 months [95%
CI 14.9–35.1]) (Po0.0001). Kaplan–Meier analysis estimated that
there were no differences in PFS according to the p-IGF-1R nuclear
expression (Figure 2A). However, the presence of high expression
nuclear p-IGF-1R (X20%) showed a significantly inferior OS
(median 16.7 months [95% CI, 13.4–20.2]) compared to low
(1–19%) (median 24.6 months [95% CI 17.8–31.5]) and negative
p-IGF-1R nuclear expression (median 30.5 months [95% CI 26.3–
31.7]) (Po0.01) (Figure 2B). Nevertheless, there was a significantly
poorer PFS according to BRAF mutation (Figure 2C). The presence
of BRAF mutation (median 11.2 months [95% CI 6.9–15.5]) or
high expression of nuclear p-IGF-1R (X20%) in wild-type BRAF
patients (median 17.5 months [95%CI 12.9–22.1]) showed a
significantly inferior OS compared to BRAF wild-type patients with
low p-IGF-1R (1–19%) (median 27.2 months [95% CI 15.1–39.3])
and negative p-IGF-1R nuclear expression (median 31.3 months
[95% CI 27.1–35.6]) (Po0.0001) (Figure 2D). In the Cox
proportional hazards model, nuclear p-IGF-1R was not significant
for PFS (Supplementary Table S2) nor OS (Table 2).
Chronic oxaliplatin treatment leads to acquired drug resistance
and induces IGF-1R nuclear localisation. In order to further
characterise how nuclear localisation of IFG-1R was associated
with treatment resistance, Colo320, DLD-1, HCT116, HT29,
SW1116, SW480, SW403, SW1463, and SW837 CRC cell lines
were treated with increasing concentrations of oxaliplatin and 5-
FU at physiologically administrated concentrations. Dose–response
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Figure 1. Expression patterns of IGF-1R: nuclear expression of p-IGF-1R increases after chemotherapy exposure but only in patients with initial
p-IGF-1R nuclear expression. (A) Patterns of expression of p-IGF-1R analysed with optical and confocal immunofluorescence microscopy.
Arrowheads denote foci of membrane p-IGF-1R expression (top panel), granular-perinuclear and dot-like endoplasmic reticulum and Golgi
patterns (middle panel), and nuclear p-IGF-1R staining (lower panel) observed in some tumours. Confocal microscope immunofluorescence shows
p-IGF-1R in red, E-cadherin (green), and nuclei stained in TO-PRO-3. (B) Summary nuclear p-IGF-1R expression. RAS and BRAFmutational status in
44 pairs of primary and metastatic samples of colorectal carcinoma is also shown. Clinical data are summarised in top rows, including response rate
by RECIST 1.1 criteria, PFS, and collection of the biopsy after treatment chemotherapy or chemotherapy plus anti-EGFR. The bottom three rows
indicate the presence of nuclear p-IGF-1R. In green are indicated negative samples (0% of cells positive), in yellow (o20%), orange (20–50%), and
red (450%) are indicated samples with different percentage measured by IHC. Asterisks indicated biopsies obtained after anti-EGFR therapy.
(C) Representative sections from IHC analysis of nuclear p-IGF-1R. Top row shows the distribution of p-IGF-1R in the primary tumour collected
before treatment; a metastatic biopsy collected after chemotherapy (oxaliplatin and 5-fluorouracil) treatment is indicated in the middle row, and a
representative metastatic biopsy collected after chemotherapy (including oxaliplatin, 5-fluorouracil, irinotecan) and anti-EGFR (cetuximab or
panitumumab) treatment is in the bottom of the panel.
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plots showed different degrees of sensitivity to the drugs
(Supplementary Figure S1A). In addition, higher concentrations
of these drugs were tested in DLD-1, HT29, and their chemo-
resistant derivates, DLD-1-OxR and HT29-OxR, showing that the
latest exhibit specific resistance to oxaliplatin alone (Supplemen-
tary Figure S1B and C). Next, we wanted to assess whether the
localisation of p-IGF-1R in the set of cell lines validated the results
observed in the primary samples. By IHC of formalin-fixed
paraffin-embedded cellular blocks, we showed an association
between resistance to oxaliplatin and 5-FU and the amount of
p-IGF-1R in the nuclear compartment (R¼ 0.604 and 0.738 for the
nine CRC cell lines and for the set of DLD-1, DLD-1-OxR, HT29,
HT29-OxR, SW1116 and HCT116, respectively (Figure 3A and
Supplementary Figures S1A and B)). To further confirm this
finding, we performed confocal microscopy immunofluorescence
with antibodies against IGF-1R and p-IGF-1R. These results
corroborated the increase of p-IGF-1R in the nucleus of HT29-
OxR compared to the parental HT29 cell line (Figure 3B). This
enrichment of the nuclear IGF-1R in the chemo-resistant HT29-
OxR and SW1116 in comparison to the chemo-sensitive HT29,
HCT116, and Colo320 was also slightly observed by western blot
(Supplementary Figures S1D and E).
To determine whether oxaliplatin had any effects on down-
stream targets of the IGF-1R signalling pathway, activation
of AKT and IRS-1 were evaluated. In a time-response experiment
using HT29 and HT29-OxR cell lines, p-AKT and p-IRS-1 are
inhibited 5min after the oxaliplatin treatment (20 mM) was
initialised, and this inhibition was sustained up to 60min in the
parental HT29; however, no effect was seen in the HT29-OxR
(Supplementary Figure S1F). In addition, we showed that low
dosage of oxaliplatin after 1-h exposure results in a reduction of
p-AKT in HT29, but not in HT29-OxR cells (Supplementary
Figure S1G).
Targeted therapies increase the localisation of IGF-1R within
the nuclear compartment. As clinical data suggested a correla-
tion between resistance to anti-EGFR compounds and nuclear
internalisation of IGF-1R, we hypothesised that these could also
be the cause of resistance to other targeted therapies, such as
ganitumab (anti-IGF-1R antibody), sorafenib (tyrosine kinase
inhibitor of VEGFR and PDGFR), and the combination of both.
Despite cellular viability was compromised upon exposure to
both drugs compared to untreated cells, no significant
differences were observed between sensitive and resistant cell
lines (Supplementary Figure S2A). Nevertheless, when we
assessed the signalling pathway activity, our results showed that
ganitumab, but not the metalloproteinase inhibitor TIMP1 or
sorafenib, inhibited the activation of AKT and IRS-1, thus
suggesting a compromise of the IGF-1R intracellular molecular
pathway upon treatment with an anti-IGF-1R antibody
(Figure 3C). In addition, depletion of the IGF-1R signalling
pathway activated apoptosis in the parental HT29 cell line;
however, in the chemo-resistant HT29-OxR line, apoptosis was
not activated (Supplementary Figure 2B).
Subsequently, we aimed at assessing whether exposure to
ganitumab, the anti-IGF-1R monoclonal antibody, and the
compound NVP-AEW541, a tyrosine kinase inhibitor of IGF-1R,
might play a role in the cellular localisation. Our results showed
that ganitumab, but not NVP-AEW541, decreased the expression
of IGF-1R in the cytosolic fraction. However, despite the fact that
expression of IGF-1R in the nuclear compartment was slightly
higher in HT29-OxR compared to the parental HT29 cells, such
levels of nuclear IGF-1R were significantly increased upon
treatment with ganitumab in both HT29 and HT29-OxR cell lines
(Figure 3D). By immunofluorescence and confocal microscopy
analysis, we did validate that total cytosolic IGF-1R expression was
depleted upon exposure to ganitumab; however, levels of p-IGF-1R
showed an increase in the nuclear compartment of HT29-OxR cells
treated with ganitumab but not NVP-AEW541 (Figure 3E).
These results were further confirmed using the parental DLD-1
and its oxaliplatin-resistant induced cell line (Supplementary
Figure S2C). Furthermore, cetuximab increased the presence of
nuclear IGF-1R in HT29-OxR cell line but did not in the parental
HT29 cell line (Supplementary Figure S2D). Interestingly, the
addition of dasatinib and dynasore, a SRC inhibitor and an
inhibitor of endocytic vesicle formation, respectively, dramatically
increased IGF-1R in the nuclear compartment of the HT29-OxR
cell line, while only a slight increase was observed in the parental
HT29 cells (Figure 3F). Finally, when these two compounds were
combined with ganitumab, the presence of nuclear IGF-1R in
HT29-OxR cells became even more prominent, indicating that
exposure to dasatinib and dynasore might not be sufficient to
impede the nuclear localisation of IFG-1R after treatment with
ganitumab.
Loss-of-function of PIAS3 and treatment with curcumin and
leptomycin inhibits IGF-1R nuclear sequestration. In order to
explore the potential molecular mechanism involved in the
translocation of IGF-1R into the nucleus when cells are exposed
to chemo-therapeutic compounds and therefore potentially indu-
cing acquired resistance, we sought to investigate the levels of the
protein inhibitor of activated STAT3 (PIAS3), as this protein is
known to retain the IGF-1R inside the nuclear compartment
Table 1. Patient characteristics according to nuclear p-IGF-1R
expression
Characteristics
Nuclear
p-IGF-1R
negative
Nuclear
p-IGF-1R
low
Nuclear
p-IGF-1R
high P-value
Number; n¼470 360 68 42
Gender (female) 121 26 15 0.75
Age, median (s.d.) 63.3 (10.4) 61.4 (10.1) 60.1 (10.6) 0.88
Surgery of primary
(yes)
244 54 26 0.09
Primary location
(right side)
79 16 13 0.405
ECOG PS 0.001
0 202 30 14
1 143 35 21
2 14 3 7
Leucocyte count
410 000
73 18 8 0.45
Alkaline phosphatase
4300U l1
58 20 12 0.013
Lactate
dehydrogenase
4ULN
107 20 16 0.13
CEA, median 334.9 705.1 316.9 0.84
Metastases, sites 41 176 36 21 0.94
Liver M1 290 54 31 0.38
Peritoneal M1 66 12 14 0.062
Genotype o0.0001
BRAF 20 8 10
RAS 90 17 2
2WT 250 43 30
GEMCAD stage 0.081
Low-risk 76 15 9
Intermediate-risk 183 35 20
High-risk 67 8 13
Abbreviations: CEA¼ carcinoembryonic antigen; ECOG PS¼Eastern Cooperative Oncol-
ogy Group Scale of Performance Status; GEMCAD¼Grupo Espan˜ol Multidisciplinar en
Ca´ncer Digestivo; IGF-1R¼ insulin-like growth factor-1 receptor; ULN=upper limit of
normal.
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(Sundvall et al, 2012). Our results revealed that nuclear
PIAS3 expression increased after treatment with ganitumab,
NVP-AEW541 and both compounds in HT29-OxR-resistant cells,
thus supporting the hypothesis that PIAS3 might be involved in the
IGFR-1R internalisation (Figure 4A).
In order to block the nuclear retention of IGF-1R, RNAi
experiments were performed. In fact, siRNAs against PIAS3 were
assayed in HT29-OxR and DLD-1-OxR cell lines demonstrating
loss-of-function at the protein level after 72 h post-transfection
(Figure 4B). Our results showed that the presence of nuclear IGF-
1R was significantly suppressed upon silencing of PIAS3 (Figure 4B
and C). We then exposed HT29 and HT29-OxR cells to curcumin
for 24 h. Curcumin has been suggested to interact with PIAS3 in
order to boost the negative effect on STAT3 activity
(Saydmohammed et al, 2010). Our results showed that curcumin
avoids, at least partially, nuclear localisation of IGF-1R in both cell
lines (Figure 4D). Similarly, when cells were treated with
leptomycin B, a specific nuclear traffic inhibitor through CRM1,
and leptomycin B with ganitumab for 24 h, we observed a decrease
in the levels of nuclear IGF-1R in HT29 and HT29-OxR
(Figure 4E). Altogether, our data indicated that PIAS3 might be
playing an active role in the maintenance of IGF-1R inside the
nucleus, and this phenomenon could potentially explain acquired
resistance.
DISCUSSION
A subset of CRC patients without BRAF mutations have a gene
expression signature and a prognosis similar to those presenting
BRAF mutations (aka., BRAF-like). In addition, roughly 13% of
2WT and 30% of KRAS mutant localised CRC patients also show a
BRAF-like signature (Popovici et al, 2012). Despite the fact that the
BRAF mutation is a solid poor prognostic marker, BRAF-like
tumours might show deregulation of specific genes such as
RANBP2 (Vecchione et al, 2016), RAC1b (Alonso-Espinaco et al,
2014), genes belonging to the CMS4 (Barras et al, 2017) or nuclear
internalisation of IGF-1R, which could also contribute to the poor
prognosis. In the present study, nuclear IGF-1R did not reach
significance in the multivariate analysis; however, we have found
that mCRC patients with BRAF mutations are significantly
enriched for the expression of nuclear IGF-1R. Because it has
been recently shown that RANBP2 is essential for survival in
BRAF-like phenotype and is implicated also in IGF-1R internalisa-
tion (Vecchione et al, 2016), we hypothesise that nuclear IGF-1R
might constitute a marker to easily identify BRAF-like phenotype
in mCRC.
Furthermore, we have investigated the patterns of IGF-1R
expression and whether IGF-1R localisation could be involved in
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mechanisms of chemotherapeutic resistance in mCRC. Assessing
the distribution of IGF-1R in a panel of 11 cell lines and 44 mCRC
samples, we observed that chemotherapy-resistant cells and pre-
treated mCRC paired biopsies showed an increment in the nuclear
expression of IGF-1R compared to sensitive cell lines and
untreated patients. We inhibited IGF-1R nuclear expression with
the monoclonal antibody IGF-1R, ganitumab, and the IGF-1R
tyrosine kinase inhibitor, NVP-AEW541. Despite the fact that
ganitumab induces cytotoxicity and inhibits phosphorylation of
IRS-1 and AKT in both HT29 and HT29-OxR, the oxaliplatin-
resistant line did not undergo apoptosis. Previously published data
showed that IGF-1R kinase activity was required for IGF-1R to
enter the nucleus (Aleksic et al, 2010; Sehat et al, 2010).
Consequently, these authors observed that tyrosine-kinase IGF-
1R inhibition suppressed IGF-1R internalisation. Interestingly, our
results showed that nuclear IGF-1R increased after ganitumab but
not with NVP-AEW541 treatment in HT29-OxR and DLD-1-OxR
cell lines. In addition, we have also observed that other compounds
shown to inhibit EGFR nuclear internalisation such as the SRC
inhibitor (dasatinib) (Li et al, 2009) also increased IGF-1R nuclear
expression.
Previous data implicated sumoylation proteins such as the
SUMO ligases (Ubc9 and RANBP2) in IGF-1R internalisation
(Sehat et al, 2010; Packham et al, 2014). We show here for the first
time that PIAS3 (another critical protein in SUMO E3 process) is
also implicated in IGF-1R nuclear internalisation in colorectal
cancer chemotherapy-resistant cells. We observed that PIAS3
increases after treatment with ganitumab and NVP-AEW541, and
this increment is still more noticeable in oxaliplatin refractory cell
lines. It has been previously published that PIAS3 promotes
Sumoylation and nuclear sequestration of ErbB4 protein (Sundvall
et al, 2012). Accordingly, after silencing PIAS3, we observed a
significant reduction of IGF-1R in the nucleus. In addition, we
have shown that curcumin and leptomycin B also reduce the
presence of IGF-1R in the nucleus, which is in agreement with the
previously reported effect of this compound on RANBP1 (Niu
et al, 2013). The consequences of IGF-1R nuclear translocation in
cancer cells are still unclear. As it has been recently described, IGF-
1R in the nucleus could be involved in the transcription regulation
of other genes (Sehat et al, 2010), and increase the promoter
activity of LEF1 downstream target genes Cyclin D1 and Axin 2 in
in vitro models of melanoma, cervical cancer and non-small cell
lung carcinoma (Aleksic et al, 2010). This phenomenon might be
of the utmost importance in colorectal cancer cells as per their
dependence on the WNT signalling pathway.
To our knowledge, these results represent the first clinical and
functional description of how nuclear IGF-1R expression might
play an active role in the acquired resistance to conventional
chemotherapy (FOLFOX, CAPOX and FOLFIRI) and targeted
therapies in mCRC. We hypothesise that patients with nuclear
IGF-1R (representing only 14% of RAS mutant and 23% of 2WT,
but 49% of BRAF mutant mCRC) are characterised by constitu-
tional overexpression of RANBP2, which facilitates the presence of
IGF-1R in the nucleus. After chemotherapy and targeted therapies
(ganitumab, NVP-AEW541 and dasatinib), PIAS3 is increased in
the nuclear compartment and contributes to the increased
expression of IGF-1R in the nucleus, which results in the activation
of the WNT pathway, previously related to chemoradiotherapy
resistance (Supplementary Figure S3) (Kendziorra et al, 2011).
In conclusion, we demonstrate that IGF-1R nuclear transloca-
tion is associated with resistance to chemotherapy and targeted
therapies both in vitro and clinically in mCRC patients, that
nuclear translocation is a process depending on PIAS3, and also
that nuclear IGF-1R might have the potential to be used as a
biomarker for poor prognosis.
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Table 2. OS, multivariate analysis for nuclear p-IGF-1R
Model 1a Model 2b
HR P-value HR P-value
Nuclear p-IGF-1R
Negative Ref. Ref.
Low 1.12 (0.81–1.54) 0.49 1.17 (0.85–1.60) 0.33
High 1.33 (0.91–1.94) 0.14 1.38 (0.95–2.01) 0.09
Gender (female)
Age 465 1.38 (1.08–1.77) 0.011
Surgery of
primary (yes)
0.64 (0.48–0.85) 0.0021 0.67 (0.51–0.89) 0.0054
Primary location
(right side)
1.35 (1.01–1.79) 0.041
ECOG PS
0 Ref. Ref.
1 2.36 (1.81–3.10) o0.0001 2.42 (1.87–3.13) o0.0001
2 8.49 (4.69–15.37) o0.0001 8.38 (4.69–14.97) o0.0001
Leucocyte count
410 000
1.44 (1.08–1.92) 0.013 1.54 (1.16–2.04) 0.0027
Alkaline
phosphatase
4300U l1
1.26 (0.88–1.80) 0.21
Lactate
dehydrogenase
4ULN
1.09 (0.74–1.60) 0.65
Metastases, sites
41
0.94 (0.71–1.26) 0.69
Liver M1
Peritoneal M1 1.34 (0.98–1.83) 0.067 1.46 (1.10–1.95) 0.0098
Genotype
RAS 1.31 (0.96–1.79) 0.086 1.31 (0.97–1.76) 0.081
BRAF 2.29 (1.52–3.44) o0.0001 2.66 (1.77–3.99) o0.0001
2WT Ref. Ref.
GEMCAD stage
Low-risk Ref. Ref.
Intermediate-
risk
2.10 (1.44–3.07) 0.0001 1.84 (1.31–2.59) 0.0004
High-risk 1.54 (0.90–2.65) 0.12 1.73 (1.11–2.71) 0.016
Abbreviations: ECOG PS¼Eastern Cooperative Oncology Group Scale of Performance
Status; GEMCAD¼Grupo Espan˜ol Multidisciplinar en Ca´ncer Digestivo; HR¼hazard ratio;
IGF-1R¼ insulin-like growth factor-1 receptor; OS¼overall survival; ULN¼ upper limit of
normal.
aModel 1 includes those variables with a P-valueo0.05 in the univariate analysis. The
variable nuclear p-IGF-1R is forced into the model.
bModel 2 selects variables using a stepwise approach with a P-value of 0.2 to enter into the
model and of a multivariate P-valueo0.05 to stay in the model. The variable nuclear p-IGF-
1R is forced into the model.
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Figure 3. Implications of targeted therapeutic agents in IGF-1R expression. (A) Summary of the mutational status of several genes implicated in
the colorectal carcinogenesis in the panel of CRC cell lines used in this study. Black indicates the presence of mutation, grey indicates deletion,
and white indicates wild-type. In yellow (o20%), orange (20–50%) and red (450%) is shown the gradient of nuclear p-IGF-1R measured by
immunohistochemistry. Numbers indicate the % of nuclear p-IGF-1R positivity. Representative images of HT29, HT29-OxR, and SW1116 illustrate
differences in the staining distribution and localisation of p-IGF-1R. (B) Confocal microscopy indicative immunofluorescence images of the location
of total IGF-1R and phospho-IGF-1R in HT29 and HT29-OxR cell lines. Fixed cells were stained with anti-IGF-1R or anti-p-IGF-1R antibodies (red)
and DAPI (blue) for nuclear counterstaining. Graphs show the percentage of viable cells 72 h after incubation with increasing dosages of a
combination of 5-FU and oxaliplatin in several CRC cell lines. Each data point represents the average value from three independent experiments.
(C) Total cells lysates from HT29 and HT29-OxR cell lines were immunoblotted against anti-p-AKT and anti-p-IRS-1 to evaluate the effect of a 24-h
exposure to ganitumab (5 mM), TIMP1 (100mM), and sorafenib (2 mM) on the IGF-1R signalling pathway. Tubulin was used as loading control.
(D) Immunoblot analysis of IGF-1R levels of nuclear and cytosolic protein extracts from HT29 and HT29-OxR cell lines were evaluated after
incubation for 24 h with ganitumab (5 mM) and NVP-AEW541 (0.1mM). Antibodies anti-HDAC1 and anti-GAPDH were used as controls for nuclear
and cytosolic fractions, respectively. Note the increase of IGF-1R in the nuclear compartment after treatment with the monoclonal antibody against
IGF-1R. (E) Representative confocal microscopy images of total and phospho-IGF-1R expression in HT29-OxR cells after incubation with ganitumab
(5mM) or NVP-AEW541 (0.1 mM) for 24 h. Cells were immunostained with IGF-1R or p-IGF-1R antibodies (red) and DAPI (blue) for nuclear
counterstaining. While membrane located IGF-1R was inhibited after treatment with ganitumab, nuclear IGF-1R markedly increased in HT29-OxR
cells. (F) Immunoblot analysis of nuclear IGF-1R in HT29 and HT29-OxR cell lines after incubation with ganitumab (5 mM), dasatinib (50 nM), dynasore
(30 nM) and their combination for 24 h. Note that in HT29-OxR, but not HT29 cells, the presence of dasatinib and dynasore without ganitumab was
able to induce expression of IGF-1R expression in the nucleus.
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Figure 4. Loss-of-function of PIAS3 prevents sequestration of IGF-1R in the nuclear compartment of chemo-resistant cells. (A) Immunoblot
analysis of PIAS3 after exposing the cells to ganitumab, NVP-AEW541, and the combination of both in HT29 and HT29-OxR cell lines. Note the
correlation between the increase of PIAS3 and nuclear IGF-1R. HDAC1 was used as loading control. (B) Transient transfection of siRNAs against
PIAS3 to HT29-OxR and DLD-1-OxR cell lines resulted in a significant knockdown of the target gene at 72 h post-transfection. Immunoblot analysis
of IGF-1R revealed a consistent increase of the protein in the nuclear compartment. HDAC1 and tubulin were immunoblotted as a loading control.
(C) Graph showing the quantification of the nuclear IGF-1R normalised to HDAC1 72h post-transfection with siRNAs against PIAS3. (D and E) HT29
and HT29-OxR cell lines were incubated for 24 h with curcumin and leptomycin B. Cytosolic and nuclear fractions were analysed by western blot
with anti-IGF-1R antibody. Loading and fraction purity were controlled by reblotting the membrane with anti-HDAC1 and anti-GAPDH antibodies.
Note that curcumin slightly decreases nuclear IGF-1R in HT29 and HT29-OxR cell lines.
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